Serial (1–3)-beta-D-Glucan (BDG) monitoring shows high variability among premature neonates
- 13 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 60 (6)
Abstract
This study aimed to characterize the baseline values and dynamics of serum (1,3)-Beta-D-Glucan (BDG) in neonates at high risk of neonatal invasive candidiasis (NIC); as well as to determine the effect of various clinical variables on these levels. Single center prospective cohort study was performed including 20 high-risk neonates (gestational age < 29 weeks and/or birth weight ≤ 1000 gr). Samples for BDG (Fungitell® assay) were obtained twice weekly during 6 weeks. Nineteen neonates were enrolled with a median gestational age of 25 weeks (IQR 24–27), median birth weight of 730 gr (IQR 650–810). None of the neonates was diagnosed with NIC. 190 serum samples were included. The median BDG value was 59 pg/ml (IQR 30–148), mean was 119 pg/ml (SD ± 154). A total of 42.1% (80/190) samples showed values ≥80 pg/ml, with all the neonates presenting at least one test above this cut-off. Neonatal age did not show an association with BDG levels. Exposure to steroids and the use of a heel prick as sampling method were associated with statistically significant higher BDG levels. The BDG levels showed high variability and in a significant proportion of samples values were above the threshold for positivity (e.g., ≥80 pg/ml) in the absence of NIC. The exposure to postnatal steroids and the heel prick as the method of blood sampling were associated with higher BDG levels. Lay Summary: Neonatal invasive candidiasis (NIC) presents high morbi-mortality. The diagnosis of NIC is often challenging. Blood cultures have limitations and better diagnostic tools are needed. Beta-D-glucan is a diagnostic marker which could be potentially used, although still more clinical data are required.Keywords
Funding Information
- Medical Research Council Canada (MR/N006364/2)
This publication has 17 references indexed in Scilit:
- Blood product transfusions are associated with an increase in serum (1-3)-beta- d -glucan in infants during the initial hospitalization in neonatal intensive care unit (NICU)The Journal of Maternal-Fetal & Neonatal Medicine, 2016
- (1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker forCandidaandAspergillusInfections of the Central Nervous System in Pediatric PatientsJournal of the Pediatric Infectious Diseases Society, 2015
- Effect of Fluconazole Prophylaxis on Candidiasis and Mortality in Premature InfantsJAMA, 2014
- Finding the “Missing 50%” of Invasive Candidiasis: How Nonculture Diagnostics Will Improve Understanding of Disease Spectrum and Transform Patient CareClinical Infectious Diseases, 2013
- (1–3)-β-D-glucan levels in candidiasis infections in the critically ill neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2012
- Serum 1,3-βD-Glucan Assay in the Diagnosis of Invasive Fungal Disease in NeonatesPediatric Reports, 2011
- Quantification of 1,3-β- d -Glucan Levels in Children: Preliminary Data for Diagnostic Use of the β-Glucan Assay in a Pediatric SettingClinical and Vaccine Immunology, 2007
- Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 MonthsPediatrics, 2006
- Evaluation of a (1→3)-β- d -Glucan Assay for Diagnosis of Invasive Fungal InfectionsJournal of Clinical Microbiology, 2005
- Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research NetworkPediatrics, 2002